Holen Sie sich die Stockscreener-App
21.94
1.62%
0.35
Handel nachbörslich:
21.94
Forte Biosciences Inc Aktie (FBRX) Neueste Nachrichten
Forte Biosciences Q1 2026 Earnings: Pre-revenue Biotech Misses EPS Estimates; Stock Dips on Narrower Loss MissGlobal Trading Community - Newser
FBRX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Pre-Revenue Biotech RealityLive Trade Sharing - Newser
FBRX Stock Price, Quote & Chart | FORTE BIOSCIENCES INC (NASDAQ:FBRX) - ChartMill
Forte Biosciences stock (US34960P1012): Q1 update keeps focus on skin disease pipeline - AD HOC NEWS
(FBRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Forte Biosciences Inc stock (US34960P1012): clinical pivot and cash focus keep biotech investors ale - AD HOC NEWS
Forte Biosciences (FBRX) price target increased by 19.72% to 65.02 - MSN
Forte Biosciences stock (US34960P1012): volatile biotech after recent sell-off tests investor nerves - AD HOC NEWS
Forte Biosciences stock (US34960P1012): New 13G filings highlight major holders - AD HOC NEWS
Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX) - Seeking Alpha
OrbiMed entities hold 5.8% of Forte Biosciences (FBRX), ownership split disclosed - Stock Titan
Point72 entities report 0% ownership in Forte Biosciences (FBRX) - Stock Titan
MPM BioImpact LLC takes a 7.2% position in Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Alger Associates (NASDAQ: FBRX) reports 1.27M shares; 10.2% stake - Stock Titan
Janus Henderson (FBRX) discloses 9.99% holding; 299,798 pre-funded warrants - Stock Titan
Forte Biosciences (NASDAQ: FBRX) deepens Q1 loss while FB102 wins Fast Track - Stock Titan
Affinity Asset Advisors takes 7.3% stake in Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Forte Biosciences stock (US34960P1012): Q1 2026 earnings report upcoming - AD HOC NEWS
Forte Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Adage (FBRX) files Schedule 13G reporting 950,000-share stake - Stock Titan
FBRX Technical Analysis | Trend, Signals & Chart Patterns | FORTE BIOSCIENCES INC (NASDAQ:FBRX) - ChartMill
Forte Biosciences stock (US34960P1012): Q1 2026 results and FDA Fast Track for FB102 - AD HOC NEWS
Chardan Capital Maintains Forte Biosciences(FBRX.US) With Buy Rating, Maintains Target Price $61 - Moomoo
MSN Money - MSN
Forte Biosciences Grants 66,667 RSUs to New Employee as Inducement - geneonline.com
New Forte Biosciences hire gets 50K options, 50K RSUs to join - Stock Titan
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - The Joplin Globe
Forte Biosciences Releases Q1 2026 Financial Results - AlphaStreet
TradingKey - TradingKey
Forte Biosciences, Inc. 1Q 2026: Net loss $(22.1M), Diluted EPS $(1.24) — 10-Q Summary - TradingView
Forte Biosciences Q1 net loss narrows as R&D spending rises - TradingView
Forte Biosciences (FBRX) widens Q1 loss and raises $172.5M to fund FB102 trials - Stock Titan
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update - The Joplin Globe
Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FDA fast-tracks celiac treatment as Forte Biosciences raises $172M - Stock Titan
FBRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Forte Biosciences (NASDAQ:FBRX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Responsive Playbooks and the FBRX Inflection - Stock Traders Daily
What Forte Biosciences (FBRX) is doing to earn customer loyalty (Breakdown Watch) 2026-05-05Wall Street Picks - newser.com
Evercore Maintains Forte Biosciences(FBRX.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Wall Street Zen Upgrades Forte Biosciences (NASDAQ:FBRX) to "Sell" - MarketBeat
Stock Traders Purchase High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
Forte Biosciences | DEF 14A: Definitive information statements - Moomoo
[ARS] Forte Biosciences, Inc. SEC Filing - Stock Titan
Forte Biosciences (NASDAQ: FBRX) 2026 proxy seeks approval of larger equity plan - Stock Titan
FBRX - Finviz
Is Forte Biosciences (FBRX) stock respecting technical levels | Q4 2025: Earnings Fall ShortCrowd Trend Signals - Newser
Understanding the Setup: (FBRX) and Scalable Risk - Stock Traders Daily
FBRX (Forte Biosciences Inc.) reports wider than expected Q4 2025 loss, with shares falling 3.52% following the earnings release.Financial Update - UBND thành phố Hải Phòng
Forte Biosciences Inc stock (US34960P1012): Is its immunology focus strong enough to unlock biotech - AD HOC NEWS
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update - MarketBeat
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):